Intralesional Immunotherapy With Mycobacteriumw Vaccine in Patients With Multiple Cutaneous Warts: Uncontrolled Open Study

Meena, Jitendra Kumar; Malhotra, Amber; Mathur, D.; Mathur, D. C.

doi:10.1001/jamadermatol.2013.866

Cited by 30 publications

(50 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 33 patients (82.5%) had complete resolution, with partial response observed in four patients (10%). Side effects were minimal, with swelling reported in 15% and fevers reported in only 5% of patients (39).…”

Section: Mycobacteriamentioning

confidence: 90%

Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature

Aldahan

Mlacker

Shah

et al. 2016

Dermatologic Therapy

103

View full text Add to dashboard Cite

Warts are common epidermal growths caused by human papillomavirus that often cause significant discomfort and embarrassment. Current treatment options include topical therapies, cryotherapy, laser vaporization, and surgical excision. Many of these options are destructive and may result in scarring, while less aggressive approaches can lead to lesion recurrence. Additionally, these local modalities are not practical for patients with a large number of warts. Systemic approaches such as immunotherapy have demonstrated success in treating multiple lesions by combining a targeted approach with upregulation of the host immune system. An extensive literature review was performed to evaluate the various vaccine antigens that have been used intralesionally to treat cutaneous and anogenital warts. The specific intralesional immunotherapies that have been studied include: Candida albicans; measles, mumps, and rubella; Trichophyton; and tuberculin antigens such as purified protein derivative, Mycobacterium w vaccine, and Bacillus Calmette-Guerin. Intralesional vaccine injection represents a safe, effective, and tolerable treatment for warts, including recalcitrant and anogenital warts. This approach has been somewhat overlooked in the past despite substantial evidence of high response rates with a low side effect profile. Large comparative trials are necessary to determine the most effective immunotherapy treatment option as well as the most appropriate dosing parameters.

show abstract

Section: Mycobacteriamentioning

confidence: 90%

Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature

Aldahan

Mlacker

Shah

et al. 2016

Dermatologic Therapy

103

View full text Add to dashboard Cite

show abstract

“…Mean time to complete response was 9.7 weeks (versus 6.75 weeks in the current study) and distant wart response was noted in 70% (versus 86.3% in current study). [27] The exact mechanism of action of Mw vaccine against viral warts is not known. Experimental evidence suggests that it leads to a strong Th1 cytokine response, especially increased production of IFN-γ, increased T cell and macrophage activation and also increasing CD8+ T cell response.…”

Section: Discussionmentioning

confidence: 99%

Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts

Singh¹,

Chouhan²,

Gupta³

2014

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

show abstract

“…The role of immunity is documented by the appearance and persistence of warts in immunosuppressed individuals. 7 Immunotherapy agents that have been tried include cimetidine, imiquimod, interferons, Candida albicans antigens, measles, mumps, rubella (MMR) vaccine, tuberculin (purified protein derivative) and intralesional vitamin D. [8][9][10][11][12] Intralesional tuberculin purified protein derivative (PPD) is effective for the warts over injected as well as distinct site and also prevents reoccurrence. Similarly vitamin D is an effective and a very recent modality used in treatment.…”

Section: Introductionmentioning

confidence: 99%

A comparative study between intralesional PPD and vitamin D3 in treatment of viral warts

et al. 2018

View full text Add to dashboard Cite

Background: Viral warts are caused by human papillomavirus. There are innumerable treatment modalities but they may result in partial clearance or recurrence. Some newer and effective treatments include intralesional immunotherapy. We undertook a study to evaluate the safety and efficacy of two such immunotherapy namely tuberculin purified protein derivative (PPD) versus intralesional vitamin D3 for the treatment of viral warts.Methods: A total of 80 patients were included in the study. Group 1 patient were injected with 10 TU of tuberculin PPD (0.1 ml) intralesional while in group 2 patients were injected (0.5 ml) vitamin D3. The clinical assessment was done by photographic measurements at baseline, before each treatment session, and after the completion of treatment.Results: In group 1 A total of 80% (32 patients) showed complete clearance and 20% (8 patients) showed partial response while in group 2 72.5% (29 patients) showed complete clearance while 27.5% (11 patients) showed partial response. No significant side effects were observed except for pain at the site of injection.Conclusions: Intralesional vitamin D and intralesional Tuberculin PPD immunotherapy shows significant results in treatment of viral warts.

show abstract

Intralesional Immunotherapy With Mycobacteriumw Vaccine in Patients With Multiple Cutaneous Warts: Uncontrolled Open Study

Cited by 30 publications

References 3 publications

Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature

Efficacy of intralesional immunotherapy for the treatment of warts: A review of the literature

Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts

A comparative study between intralesional PPD and vitamin D3 in treatment of viral warts

Contact Info

Product

Resources

About